← Eichor
Study identifier: NCT04916613 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Condition: Prostate Cancer Metastatic  ·  Sponsor: UNICANCER

PhasePhase 3
Planned participants300
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors.

This description comes directly from the study's public registry record.

Talk to the study team

Catherine N LEGER  ·  +33 (0) 1 85 34 31 13  ·  c-leger@unicancer.fr

Rachida KHERRAZ  ·  +33 (0) 1 80 50 15 99  ·  r-kherraz@unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (95)

Grand Hopital de Charleroi - site Notre DameCharleroi, BelgiumRecruiting
Groupe Jolimont - Hôpital De JolimontHaine-Saint-Paul, BelgiumRecruiting
CHU UCL NAMUR - Site STE. ELISABETHNamur, BelgiumRecruiting
Clinique Saint PierreOttignies, BelgiumRecruiting
Institut Sainte CatherineAvignon, FranceRecruiting
Centre Hospitalier Cote basqueBayonne, FranceRecruiting
CHU Besançon - Hopital Jean MijozBesançon, FranceRecruiting
Centre Pierre CurieBeuvry, FranceRecruiting
Centre Institut BergoniéBordeaux, FranceRecruiting
Clinique PasteurBrest, FranceRecruiting
Centre François BaclesseCaen, FranceRecruiting
Centre Hospitalier Métropole SavoieChambéry, FranceRecruiting

+ 83 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04916613